


Vidarbha Youth Welfare Society's  
**INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH**  
Borgaon (Meghe), Wardha (M.S.)

**Representative documents for collaborative activities 2020- 21**

**Table of content**

<b>Sr. No.</b>	<b>Name of Institution/Industry</b>	<b>Activity</b>	<b>Page No.</b>
1	Datta Meghe Institute of Medical Sciences, Sawangi, Wardha.	Formulation of gel and sugar candy	01-04
2	Maharashtra Centre for Entrepreneurship Development (MCED), Nagpur	Webinar on 'Entrepreneurship and Innovation as Career Opportunity'	05-12
3	Siddhayu Ayurvedic Research Foundation Pvt. Ltd. Nagpur	Acute toxicity studies	13-41
4	Siddhayu Healthcare Pvt. Ltd. Mumbai	Acute toxicity studies	42-132



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

DattaMeghe Institute of Medical Sciences  
(Deemed to be University)  
**SHARAD PAWAR DENTAL COLLEGE & HOSPITAL**

Sawangi (Meghe), Wardha, -442 004

Ph. 243542,240808,240129,243037,245968, Fax - 07152-241711.

E-Mail : deanspdc@gmail.com Visit At : www : dmims.org.



REF NO: SPDC/PEDO/2019-20/447

Date: 20/3/2020

To,  
The Principal,  
Institute of Pharmaceuticals Education and Research  
Wardha

Subject: Permission for formulation of Research material.

Respected Sir,

I, Dr. Sphurti Bane, the undersigned Post Graduate Student of Department of Pediatric and Preventive dentistry, Sharad Pawar Dental College would like to request you to kindly allow me to work in your Institute for preparation of formulation of my research material. The materials required for the same will be arranged from my side.

It is requested to kindly permit me to use your Institute facilities.

Thanking you.

Yours Sincerely,

Dr. Sphurti Pramod Bane  
Principal Investigator,  
Post Graduate student,  
Department of Pediatric and Preventive  
Dentistry,  
Sharad Pawar Dental College,  
Wardha.

Permitted

Dr. Nilima Thosar  
Guide,  
Professor and HOD,  
Department of Pediatric and Preventive  
Dentistry,  
Sharad Pawar Dental College,  
Wardha.

Dr. Sudhindra Baliga  
Dean,  
Department  
Dentistry  
Sharad Pawar  
Wardha.



(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Meghe), Wardha



Estd : 1991

VIDARBHA YOUTH WELFARE SOCIETY'S

# INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Borgaon (Meghe), Wardha, Maharashtra State, India - 442 001

NAAC accredited Grade 'A'

Dr. R. O. Ganjiwale  
I/C. Principal

Ph. 07152 -240284  
Fax 07152-241684

E-mail: iper4160@gmail.com  
Web Side: www.iperwardha.com

Conducting Degree, Post Graduate and Doctorate Programme in Pharmaceutical Sciences



# INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Borgaon (Meghe), Wardha, Maharashtra State, India - 442 001

NAAC accredited Grade 'A'

Ph. 07152 -240284  
Fax 07152-241684

E-mail: iper4160@gmail.com

Date -29.10.2020

Conducting Degree, Post Graduate and Doctorate Programme in Pharmaceutical Sciences

## TO WHOMSOEVER IT MAY CONCERN


This is to certify that Dr. Spurthi Pramod Bane, a postgraduate student of Department of Pediatric and Preventive Dentistry, Sharad Pawar Dental College and Hospital, Sawangi, Wardha has successfully formulated the herbal and placebo lollipops for her thesis titled "**Comparative evaluation of antibacterial efficacy of *Emblica Officinalis* lollipops against *Streptococcus mutans* in institutionalized visually impaired children – A prospective study**" using facilities available at Institute of Pharmaceuticals Education and Research, Borgaon (Meghe), Wardha.


  
Dr. Shagufta Khan.

Dept. of Pharmaceutics,


Institute of Pharmaceuticals Education and Research, Wardha

Reviewed on 29/10/2020

  
(Dr. Spurthi Bane)

  
(Dr. R. O. Ganjiwale)  
I/c Principal



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

Institution & Research  
Wardha

Datta Meghe Institute of Medical Sciences  
(Deemed to be University)  
**SHARAD PAWAR DENTAL COLLEGE & HOSPITAL**

Sawangi (Meghe), Wardha, -442 004  
Ph. 243542,240808,240129,243037,245968, Fax - 07152-241711.  
E-Mail: deanspdc@gmail.com Visit at: www: dmims.org.



Date: 28/11/2020

To,  
The Principal,  
Institute of Pharmaceutical  
Education and Research,  
Borgaon (Meghe), Wardha.

Subject: Permission for formulation of Research material.

Respected Sir,

I, Dr .Nilima Thosar, Head and Professor ,Pediatric and Preventive Dentistry, Sharad Pawar Dental College requires formulation preparation of my research material from your institute. I would like to request you to allow me for the same.The materials required for the formulation preparation will be arranged from my side.

It is requested to kindly permit me to use yourInstitute facilities.

Thanking you.

Yours Sincerely,

Dr. Nilima Thosar  
Guide, Professor and HOD,  
Department of Pediatric and Preventive  
Dentistry,  
Sharad Pawar Dental College,  
Wardha.

Dr. Sudhindra Baliga  
Dean,  
Department of Pediatric and Preventive  
Dentistry,  
Sharad Pawar Dental College,  
Wardha.

*forwarded  
shan*

*Sir, ask to  
pay RS 500/-  
It was only  
formulation*

*807/2020*

Receipt No  
53488

Dated  
28/11/2020



(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

Estd : 1991

VIDARBHA YOUTH WELFARE SOCIETY'S

INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH

Borgaon (Meghe), Wardha, Maharashtra State, India - 442 001

Ph. 07152 -240284 Fax 07152-241684

Nitin R. Dhande  
President

Adv. Uday S. Deshmukh  
Vice President

Prof. (Dr.) Hemant M. Deshmukh  
Treasurer

Shri. Yuvrajsingh V. Choudhary  
Secretary

Dr. R. O. Ganjiwale  
I/c Principal

E-mail: iper4160@gmail.com  
Web Side: www.iperwardha.com

Conducting Degree, Post Graduate and Doctorate Programme in Pharmaceutical Sciences

Date: 17/12/2020

To WHOMSOEVER IT MAY CONCERN

This is to certify that Dr. Nilima Thosar, Head and Professor, Pediatric and Preventive Dentistry, Sharad Pawar Dental College, Sawangi, Wardha has successfully formulated dental gel using the facilities available at the Institute of Pharmaceutical Education and Research, Borgaon (Meghe) Wardha.

Dr. Shagufta Khan  
Professor  
Department of Pharmaceutics



*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha



Vidarbha Youth Welfare Society's

**INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH**

*Borgaon (Meghe), Wardha*

*and*

**MAHARASHTRA CENTRE FOR ENTREPRENEURSHIP DEVELOPMENT (MCED)**

*Nagpur*

**Jointly Organizes Webinar on 21<sup>st</sup> May 2021 at 2.30 pm**



Under IQAC and Entrepreneurship Development Cell of the Institute



*Topic*

**“Entrepreneurship and Innovation as Career Opportunity”**

**Outcome :**

- 1. To raise awareness about Entrepreneurship as a career option.**
- 2. To promote innovation and start-ups in the Institute.**

**Mr. Alok Mishra**

*Regional Officer, MCED  
Nagpur*

Zoom Meeting

Jyotiranjn Alok Mishra N Nandini Kale Abhiram Desh... Shagufta Khan

HR WAGHMARE PO MCED

9:21 AM

Zoom Meeting

Yogita sahu Abhiram Desh... Alok Mishra Shagufta Khan

ENTREPRENEURSHIP

- An entrepreneur is a person who stood for what he/she believed in and was able to **transform** the lives of others through his/her **action**". – i.e.

Mobile, Microwave, V

HR WAGHMARE\_PROJECT OFFICER/MI

(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Steph), Wardha

Participants (50)

Find a participant

Jyotiranjn (Co-host, me)

Abhiram Deshmukh (Host)

HR WAGHMARE... (Co-host)

Aachal Borkar

Chat

Nikhita Sawane

From Ujwal Havelikar to Everyone:

m.pharma (Pharmaceutics)  
Roll No-14  
Ujwal Havelikar

9:21 AM

Zoom Meeting

Yogita sahu Abhiram Desh... Alok Mishra Shagufta Khan

ENTREPRENEURSHIP

- An entrepreneur is a person who stood for what he/she believed in and was able to **transform** the lives of others through his/her **action**". – i.e.

Mobile, Microwave, V

HR WAGHMARE\_PROJECT OFFICER/MI

(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Steph), Wardha

Participants (50)

Find a participant

Jyotiranjn (Co-host, me)

Abhiram Deshmukh (Host)

HR WAGHMARE... (Co-host)

Aachal Borkar

Chat

Nikhita Sawane

From Ujwal Havelikar to Everyone:

m.pharma (Pharmaceutics)  
Roll No-14  
Ujwal Havelikar

9:21 AM

# Abhiram Deshmukh Iper

7 photos • May 22, 2021



9:21 AM

Zoom Meeting

Jyotiranjana Alok Mishra N Nandini Kale Abhiram Desh... Shagufta Khan

9:21 AM

Zoom Meeting

Yogita sahu Abhiram Desh... Alok Mishra Shagufta Khan

**ENTREPRENEURSHIP**

- *An entrepreneur is a person who stood for what he/she believed in and was able to **transform** the lives of others through his/her **action**". – i.e. **Mobile, Microwave, WhatsApp...***

Participants (50)

Find a participant

- Jyotiranjana (Co-Host, me)
- Abhiram Deshmukh (Host)
- HR WAGHARE (Co-Host)
- Aashil Borkar

Chat

Nikita Basore

From Local Notification to Everyone

mypharma (Pharmaceutical)

Roll No-14

Ujjwal Havelikar

9:21 AM

(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha


**INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH**  
Borgaon (Meghe), Wardha

and  
**MAHARASHTRA CENTRE FOR ENTREPRENEURSHIP DEVELOPMENT (MCED)**  
Nagpur

Jointly Organizes Webinar on 21<sup>st</sup> May 2021 at 2:30 pm

7





Zoom Meeting

Shagufta Khan is talking...

Meeting is now streaming live on YouTube

Participants (44)

Find a participant

- Jyotiranjn (Co-host, me)
- Abhiram Deshmukh (Host)
- HR WAGHMARE PO ... (Co-host)
- Alok Mishra
- Shagufta Khan
- Dr Ganjwale
- Aachal Borkar
- Aarti Butale
- Ajay Turke
- Aniket wadaskar
- Ankita Thul
- Dilesh Singhavi

Unmute Start Video Security Participants Chat Share Screen Record Reactions Leave

Search for anything

9:21 AM

Zoom Meeting

Jyotiranjn

Shagufta Khan

Dr Ganjwale

Girish Dahikar

Participants (45)

Find a participant

- Jyotiranjn (Co-host, me)
- Abhiram Deshmukh (Host)
- HR WAGHMARE PO ... (Co-host)
- Alok Mishra
- Dr Ganjwale
- Aachal Borkar
- Aarti Butale
- Ajay Turke
- Aniket wadaskar
- Ankita Thul
- Dilesh Singhavi
- Dipali Masurkar

Unmute Start Video Security Participants Chat

Search for anything


9:21 AM



(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Moghe), Wardha

LIVE on YouTube

View



Jyotiranjn



HR WAGHMAR...

You can release your video order here

Girish Dahikar

Lalit Rathi

Minal k gharpure

Nandini Kale

Samiksha

Connecting to a...

allavi Nikhade



Aarti Butale

Ankita Thul



1/2

1/2

Priyanka Durgu...

Payal kawale



Ujwal Havelikar



Neha deotare



Mayuri Rangari

Shivani

Vrukshali Wank...

Unmute Start Video Security Participants 43 Chat Share Screen Record Reactions Leave

Participants (43)


Find a participant

- Jyotiranjn (Co-host, me)
- Abhiram D.. (Host) Mute More
- HR WAGHMARE PO... (Co-host)
- Alok Mishra
- Shagufta Khan
- Dr Ganjiwale
- Aachal Borkar
- Aarti Butale
- Ajay Turke
- Ankita Thul
- Dilesh Singhavi
- Dipali Masurkar

Invite Mute All

# ← Abhiram Deshmukh Iper

7 photos • May 22, 2021




Webinar on “Entrepreneurship and Innovation as Career Opportunity” held at IPER on 21/5/21

The IQAC and the Entrepreneurship Development Cell of the IPER in the concerted initiative organized a webinar on “Entrepreneurship and Innovation as Career Opportunity” in collaboration with the Maharashtra Centre for Entrepreneurship Development, Nagpur on 21/5/21. The objective of the webinar was to enlighten the spirit of self-employment among students.

Shri. Alok Mishra, Regional Director and Shr. Hemant Wankhede, Project Manager, MCED, Nagpur were the resource person. Shr. Hemant Wankhede gave motivating presentation by sharing history of some very successful great entrepreneurs of India. He apprised the participants with the Government initiatives and scheme to start small and medium enterprises. He also highlighted the thrust area for business where prosperity is evident.

Dr. R. O. Ganjiwale, Principal, IPER and Dr. L. G. Rathi, Incharge, IQAC were present on the occasion. The program was conducted by Dr. Shagufta Khan, In-charge Entrepreneurship Development Cell, IPER conducted the program. Technical Support was provided by Mr. Abhiram Deshmukh, Assisst. Professor, IPER. About 50 students attended the program.



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgonou (Moghe), Wardha

Ref No.: SARF/2020-21

Date: 31.08.2020

To,  
The Principal,  
Institute of Pharmaceutical Education and Research,  
Borgaon, Wardha.

Subject: Sample for acute toxicity study.

Dear Sir,


With reference to our discussion, we are sending herewith following samples for acute toxicity.

Sr No.	Name of Product	Batch No.	Mfg Date.	Expiry Date	Weight	Qty in No's
1	Termino Spot on	VTS04	03/2020	02/2023	30 ml	02
2	Respi-SID Poultry	VRPP04	03/2020	02/2023	100 ml	02
3	Renosid Poultry	VRP05	03/2020	02/2023	100 ml	02

Kindly acknowledge the receipt of the same and start the work.

Thanking you.


Yours Faithfully,



S.S. Dhurde

(Authorized Signatory)



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

Reg. Off. :- 404, Chartered House, Dr. Cawasji Harnosji Street, Mumbai - 400002.

Factory At :-

Bahadura :- Post - Kaimana (Acharya), Umrer Road, Bahadura, - Dist. Nagpur - 441 204. Ph. No.: 07103-278115

Wadsa :- Lakhandur Road, Desaijanj Wadsa, - Dist. Gadchiroli - 441 207 Ph. No.: 07137-272858

# PROJECT REPORT

## ACUTE DERMAL TOXICITY STUDY OF TERMINO SPOT ON

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



**Performing Department**

Department of Pharmacology,

Institute of Pharmace

Borgaon



*(Signature)*  
(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

SEPETMBER 2020

## REPORT

### STUDY TITLE

# ACUTE DERMAL TOXICITY STUDY OF TERMINO SPOT ON

### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009

### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440 009

Date of commencement: 8<sup>th</sup> September 2020 to 24<sup>th</sup> September 2020

### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha


### Co-Principal Investigator

**Mr. Jyotiranjn Roul**

Assi

Department  
Institute of Pharmaco  
Borgaon (Meghe), Wardha



  
(Dr. R. O. Ganjiwale)  
Principal


PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha



## TABLE OF CONTENT

SR. NO.	TITLE	PAGE NO.
1.	INTRODUCTION	4
2.	MATERIALS AND METHODS	4
3.	RESULTS	8
4.	DISCUSSION	12
5.	CONCLUSION	12
6.	REFERENCE	13



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

### LIST OF TABLES

TABLE NO.	TITLE	PAGE NO.
1.	GROUPS OF ANIMALS	5
2.	MEAN BODY WEIGHT	8
3.	MORTALITY	8
4.	FOOD CONSUMPTION (g / animal)	9
5.	BIOCHEMICAL FINDING	9
6.	PATHOLOGY FINDINGS	9

### LIST OF PLATES

PLATE NO.	TITLE	PAGE NO.
1.	Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100	10
2.	Histopathological Studies of Kidney (Group II (2000 mg/kg) (H&E) X100	10
3.	Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400	11
4.	Histopathological Studies of Heart (Group II 2000 mg/kg) X400	11



## 1. INTRODUCTION

Acute dermal toxicity is the adverse effects occurring within a short time of dermal application of a single dose of a test substance. In the assessment and evaluation of the toxic characteristics of a substance, determination of acute dermal toxicity is useful where exposure by the dermal route is likely. It provides information on health hazards likely to arise from a short-term exposure by the dermal route. Data from an acute dermal toxicity study may serve as a basis for classification and labelling. It is an initial step in establishing a dosage regimen in subchronic and other studies and may provide information on dermal absorption and the mode of toxic action of a substance by this route. (OECD Guideline 402)

### OBJECTIVE:

To determine the acute dermal toxicity (if any) of the test sample **Termino Spot on** (Batch No. VTS04) supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd, Nagpur.

### PRINCIPLE:

The test substance is applied to the skin in graduated doses to several groups of experimental animals, one dose being used per group. Subsequently, observations of effects and deaths are made. Animals which die during the test are necropsied. The surviving animals are sacrificed and necropsied. Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Dosing test substances in a way known to cause marked pain and distress due to corrosive or irritating properties need not be carried out. (OECD Guideline 402)

## 2. MATERIALS AND METHODS

**Test Substance:** The supplier provided for the test container containing cream identified as **Termino Spot on** (Batch No. VTS04)

The test substance was stored at ambient temperature and out of the light

### Details of test animals


**Species:** Albino rats weighing in rang

**Strain:** Wistar

**Sex:** Female

**Number of animals per dose level:** 3



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Mighe), Wardha

**Number of groups:** 2

**Selected doses:** 200 and 2000 mg/kg

**Rationale of selection:** As per OECD 402 guidelines

**Housing and feeding conditions**

Animals were caged individually. The temperature of the experimental animal room was 22°C ( $\pm 3^\circ$ ) and the relative humidity 30-70 per cent. Cages maintained at 12 hr of light and dark cycle in the animal house of the Institute.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Allocation of animals to various groups:**

**Table No. 1. GROUPS OF ANIMALS**

Group No.	Dose (mg/kg b. Wt) Topically	Animal Numbers
I	200	1 - 3
II	2000	4 - 6

### Preparations


Healthy young adult rats were acclimatized to the laboratory conditions for 5 days prior to the test. Before the test, animals were randomized and assigned to the treatment groups. Approximately 24 hours before the test, fur was removed from the dorsal area of the trunk of the test animals by shaving. Care was taken to avoid abrading the skin, which could alter its permeability.

About 10 per cent of the body surface area was clear for the application of the test substance.

### EXPERIMENTAL:

The animals were fasted overnight prior to the test. Following the period of fasting, the animals were divided into two groups. The test sample was applied on the fur-removed skin. After the application of test sample food was withheld for 1-2 hours. If the compound are likely to be non-toxic i.e. having toxicity



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

withheld.  
le was

only above regulatory limit dose then, the dose level to be used as the starting dose is selected as 200 mg/kg b. wt. Accordingly, the first dose in this study was 200 mg/kg (topically) and after that as no toxicity occurred; a limit test dose of 2000 mg/kg b. wt. (topically) was taken. Body weight of the entire test animal was recorded before and periodically (weekly) after administration of the test sample. The animal were observed for 24 hours, then for further 1 days for death and manifestation of toxic effects like changes in skin and fur, eyes and mucous membranes and also any changes in respiratory, circulatory, CNS, autonomic, somatic activity and behaviour pattern if any was recorded. The important clinical sign like muscular tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma if any observed during study period were recorded.

### **Acute Dermal Toxicity (OECD-402)**

For the product of topical application, the testing was undertaken as per OECD-402 guidelines to conduct acute dermal toxicity study test. The Original acute dermal toxicity guideline 402 was adopted in 1987. In this study, both local and systemic effects were investigated. For acute dermal toxicity test 06 Wister rats were procured from CPCSEA registered breeding source i.e. Small Animal Facility, of IPER, Wardha and the test was conducted as per OECD-402 guidelines.

### **OBSERVATIONS:**

The animals were clinically observed twice on the day of the dosing and once daily thereafter for 14 days.

#### **1. Clinical signs:**

All animals were observed daily for clinical signs such as gross changes in the activity and the behavioral pattern. They were also observed for the presence of tremors, convulsions, salivation, diarrhea and lethargy.


#### **2. Body weight:**

The mean group body weight of the control and test group animals were recorded on 0<sup>th</sup> day, 7<sup>th</sup> day and 14<sup>th</sup> day.

#### **3. Mortality:**

All animals were observed twice daily for mortality during the period of the study.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Mighe), Wardha

#### 4. Food consumption:

The quantities of food consumed by control and test groups were recorded on 0<sup>th</sup> day, 7<sup>th</sup> day and on 14<sup>th</sup> day.

#### 5. Biochemical Parameters:

- Aspartate aminotransferase (AST),
- Alanine transaminase (ALT),
- Alkaline phosphatase (ALP),
- Creatinine

#### 6. Gross pathology and Histopathology:

All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically. Gross pathology and histopathological examination of lung, Liver, Kidney, and heart were conducted.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings histopathological examination
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg <
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



*(Signature)*  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Moghe), Wardha

### 3. RESULTS

#### Clinical signs:

All the groups were free of intoxication signs throughout the period of study.

#### Body weight:

Animals from control and test groups exhibited normal and comparable body weight gain throughout the period of study. (Table No. 2)

**Table No. 2 INDIVIDUAL BODY WEIGHT**

Group No.	Dose (mg/kg) Topically	Rats No.	Body weight (g)		
			0 <sup>th</sup> day	7 <sup>th</sup> day	14 <sup>th</sup> day
I	200	1	220	228	234
		2	225	234	240
		3	220	229	240
		<b>Mean±SD</b>	221.67±289	230.33±3.21	238.00±3.46
II	2000	4	234	242	249
		5	230	238	245
		6	221	231	240
		<b>Mean±SD</b>	228.33±6.66	237±5.57	244.67±4.51

Values expressed as mean ± standard deviation

#### Mortality: (Table No. 3)

All animals from control group and test group survived throughout the study for 14 days.

**Table No. 3 MORTALITY**

Under the condition of the present study, the following mortality rates were recorded

Group No.	Dose (mg/kg) Body weight (g) topically	Mortality
I	200	0/3
II	2000	



(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgunor (Moghe), Wardha

Food consumption

Table No. 4 GROUP MEAN FOOD CONSUMPTION (g / animal)

Group No.	Dose (mg/kg)	Day		
		0 <sup>th</sup>	7 <sup>th</sup>	14 <sup>th</sup>
I	200	11	14	15
II	2000	12	14	13

Biochemical Parameter

Table No. 5: BIOCHEMICAL FINDING

Group No.	Dose	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	Creatinine (mg/dL)
I	200 mg/ kg b. wt topically	49.67±2.52	68.00±5.29	77.67±7.51	1.37±0.15
II	2000 mg/ kg b. wt topically	59.67.33±2.52	81.67±2.08	84.67±4.93	1.47±0.32
Significance /NS		NS	NS	NS	NS

Values are expressed as mean ± SD, NS=Non significant

**Gross pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table 5.

Table No. 6 PATHOLOGY FINDINGS

Group No.	Death		Comments
	Day	Reason	
I	Day 15	Sacrifice	NTR
II	Day 15	Sacrifice	NTR

NTR = nothing to report

**Histopathology:** Section from liver shows perivascular lymphoid aggregation. Section from Lung shows mild pneumoni



(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

th mild  
irkable.



PLATES




Plate 1: Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100



Plate 2: Histopathological Stud

(H&E)



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Mighe), Wardha



**Plate 3: Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400**



**Plate 4: Histopathological Stud**



*(Signature)*  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Moghe), Wardha

100

#### 4. DISCUSSION:

1. The animals treated at different dose levels with the above test compound Termino Spot on (Batch No. VTS04) in all the groups exhibited normal activity and behavioral pattern.
2. There were no clinical signs of tremors, convulsions, exophthalmia, salivation, diarrhea and lethargy.
3. Animals exhibited normal and comparable body weight gain throughout the period of study.
4. Food intake of normal and animals treated at different dose levels was found to be comparable throughout the tenure of the study.
5. The pathology finding shows no abnormality in any group of animals.

#### 5. CONCLUSION:


The above findings revealed that the Termino Spot on (Batch No. VTS04) supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd, Nagpur was found to be safe at doses 200 and 2000 mg/kg when applied locally. None of the animals were found to be moribund condition in all the groups until the 14 days of the study.

The Study has indicated that Termino Spot on (Batch No. VTS04) at dose of 2000 mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of Termino Spot on (Batch No. VTS04) was more than 2000 mg/kg.

## REFERENCES

1. OECD Guideline for Testing of Chemicals, Acute oral Toxicity – Fixed Dose Procedure, 402. Organization for Economic Co-operation and Development, Paris, 9<sup>th</sup> October 2017.
2. OECD – Harmonized Integrated Hazard Classification System for Human Health and Environmental Effects of Chemical Substances – as endorsed by the 28<sup>th</sup> Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, November 1998.
3. OECD (2000) – Guidance Document on the Recognition Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment No. 19.


**Project coordinator** : Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal Investigator** : Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator** : Mr. Jyotiranjjan Roul  
Assistant Professor





  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

SEP



*(Dr. R. O. Ganjiwale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

#### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

#### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

Date of commencement: 14<sup>th</sup> September 2020 to 28<sup>th</sup> September 2020

#### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

#### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

#### Co-Principal Investigator

**Mr. Jyotiranjn Roul**

Assistant Professor

Department  
Institute of Pharmaco  
Borgaon




*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

<b>I. AIM AND OBJECTIVES</b>	<b>3</b>
<b>II. TEST SUBSTANCE</b>	<b>3</b>
<b>III. TEST ANIMALS</b>	<b>4</b>
<b>IV. TEST PROCEDURE</b>	<b>4</b>
<b>V. OBSERVATIONS</b>	<b>5</b>
<b>VI. RESULTS</b>	<b>6</b>
<b>VII. CONCLUSION</b>	<b>6</b>
<b>VIII. REFERENCES</b>	<b>7</b>
<b>APPENDICES</b>	



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as **Respi-SID Poultry** (Batch No. VRPP04).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Meghe), Wardha



### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** As per information provided by sponsor, the provided liquid formulation is concentrated and should be used with dilution. The highest dose of formulation that can be used is 250 ml in 1000 liter water. So the test substance was diluted accordingly.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.

The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the method described in the Annex 2 of the OECD guideline 420 (joined in Appendix F) with 5 animals receiving the test substance per body weight.



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoo (Moghe), Wardha

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg

- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg

- Category 5 = LD<sub>50</sub> > 2000 mg/kg

- Category 5 or non classified



*(Dr. R. O. Ganjivale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgunor (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Respi-SID Poultry** (Batch No. VRPP04), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Respi-SID Poultry** (Batch No. VRPP04) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Respi-SID Poultry** (Batch No. VRPP04) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

**Principal investigator**


: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



I.P.E.R. WARDHA

  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

*Submitted to*

*Siddhayu Ayurvedic Research Foundation Pvt. Ltd,  
Nagpur 440009*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

SEP



*(Dr. R. O. Ganjiwale)*  
**Principal**  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

### Sponsored by

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

### Submitted to

Siddhayu Ayurvedic Research Foundation Pvt. Ltd.  
Nagpur, 440009

Date of commencement: 14<sup>th</sup> September 2020 to 28<sup>th</sup> September 2020

### Project coordinator

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

### Principal investigator

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha


### Co-Principal Investigator

**Mr. Jyotiranjana Roul**

Assistant Professor

Department  
Institute of Pharmace  
Borgaon




  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.

This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as **Renosid Poultry** (Batch No. VRP05).

The test substance was stored at ambient temperature and out of the light.



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL

Institute of Pharmaceutical Education & Research

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix IV) 5 animals were divided into two groups formed with 5 animals receiving the test sub and 5 animals receiving the control. The body weight.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha



## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>1</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were sacrificed by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Wardha), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.


**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Renosid Poultry** (Batch No. VRP05), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Naggur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Renosid Poultry** (Batch No. VRP05) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Renosid Poultry** (Batch No. VRP05) was more than 2000 mg/kg.

**Project coordinator** : Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha



**PRINCIPAL**

Institute of Pharmaceutical Education & Research  
Borgasur (Mogha), Wardha.


**Principal investigator** : Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator** :



I.P.E.R. WARDHA



(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgasur (Mogha), Wardha

# SIDDHAYU HEALTHCARE PRIVATE LIMITED



**SIDDHAYU**  
REIMAGINING HEALTHCARE

Off: Flat No. 704, 7th Floor, Pratik Plaza  
Cardinal Brachios Road, Chakala, Mumbai 400099  
Corporate Office: Great Nag Road, Nagpur 440024  
Ph. No. 0833705118 / 0920303477

Ref No: SHPL/2020-21/

Date: 17/08/2020

To,  
The Principal,  
Institute of Pharmaceutical Education and Research,  
Borgaon, Wardha.

Subj: Sample for acute toxicity study.

Dear Sir,


With reference to our discussion, we are sending herewith following samples for acute toxicity.

Sr. No.	Name of Product	Batch No.	Mfg.Dt.	Exp.Dt.	Qty in Nos
1	Diabo Yogue(5202390001)				1 Nos
2	Sleep Yogue(5202370001)				1 Nos
3	Cof Yogue(5202320001)				1 Nos
4	Spiruactiv(5202380002)				1 Nos
5	Winostress(5201030001)				1 Nos
6	Painquit(5202420001)				1 Nos
7	ChyawanYogue(5202460001)				1 Nos
8	Diabo Yogue(1301)				1 Nos
9	Heart Yogue(5202330001)				1 Nos
10	Immune Yogue(5202470001)				1 Nos
11	Digee Yogue(5202350001)				1 Nos
12	Turmeric Yogue(5202400001)				1 Nos


Kindly acknowledge the receipt of the same and start the work.

Thanking you.

Yours Faithfully

  
S. S. Dhurde  
(Authorised Signatory)



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd. Nagpur, 440024


**Submitted to**  
Siddhayu Healthcare Pvt. Ltd. Nagpur, 440024

Date of commencement: 8<sup>th</sup> September 2020 to 24<sup>th</sup> September 2022

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha




  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Moghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing Tablets identified as Diabo Yogue (Batch No. 5202390001).

The test substance was stored at am



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was dissolved in water.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.

The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2000 mg/kg.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix I with 5 animals receiving the test sub weight.



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

formed  
of body



## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg


- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg

- Category 5 = LD<sub>50</sub> >

- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Diabo Yogue** (Batch No. 5202390001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Diabo Yogue** (Batch No. 5202390001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Diabo Yogue** (Batch No. 5202390001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**

: I   
I.P.E.R. Wardha

  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 7<sup>th</sup> September 2020 to 23<sup>th</sup> September 2020


**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjjan Roul**  
Assistant Professor

Department  
Institute of Pharmac  
Borgaon



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



*(Dr. R. O. Ganjiwale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoo (Stephe), Wardha

## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.

This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing Capsule identified as Sleep Yogue (Batch No. 5202370001).

The test substance was stored at ambient temperature and out of the light.



*(Signature)*  
(Dr. R. O. Ganjivale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was dissolved in water.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2000 mg/kg.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix IV of the present report) the test was performed with 5 animals receiving the test sub  
weight. body



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> > 2000 mg/kg
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Astege), Wardha



## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Sleep Yogue** (Batch No. 5202370001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a  $LD_{50}$  higher than 2000 mg/kg in the Rat.

The Study has indicated that **Sleep Yogue** (Batch No. 5202370001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Sleep Yogue** (Batch No. 5202370001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha



**PRINCIPAL**

**Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.**

**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



(Dr. R. O. Ganjiwale)

**Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha**

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe) Wardha**

SEPI



*(Dr. R. O. Ganjiwale)*

**Principal**

**PRINCIPAL**

**Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha**

# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024


Date of commencement: 7<sup>th</sup> September 2020 to 23<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjn Roul**  
Assistant Professor  
Department of Pharmacology,  
Institute of Pharmace  
Borgaon




  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as **Cof Yogue** (Batch No. 5202320001).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Meghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 200-220 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix IV of the present report) the test was performed with 5 animals receiving the test s  
weight.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> > 2000 mg/kg
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Mighe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance Cof Yogue (Batch No. 5202320001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that Cof Yogue (Batch No. 5202320001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of Cof Yogue (Batch No. 5202320001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R, Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha.


**Principal Investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R, Wardha



**Co-Principal Investigator**



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha



# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

SEPI



*(Dr. R. O. Ganjiwale)*  
**Principal**  
**PRINCIPAL**  
**Institute of Pharmaceutical Education & Research**  
**Borgaon (Meghe), Wardha**

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 7<sup>th</sup> September 2020 to 23<sup>rd</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjn Roul**  
Assistant Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (




*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Moghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing Capsule identified as **Spiruactiv** (Batch No. 5202380002).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 190-210 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was dissolved in water.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2000 mg/kg.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix IV of the present report) the test was performed with 5 animals receiving the test substance at a dose of 2000 mg/kg of body weight.



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Meghe), Wardha

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were - changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were sacrificed by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg


- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg

- Category 5 = LD<sub>50</sub> > 2000 mg/kg

- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Spiruactiv** (Batch No. 5202380002), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Spiruactiv** (Batch No. 5202380002) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Spiruactiv** (Batch No. 5202380002) was more than 2000 mg/kg.


**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

Submitted By

Project coordinator  
Dr. R. O. Ganjiwale  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

Principal investigator  
Dr. B. R. Gandhare  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



Performing Department  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



*(Dr. R. O. Ganjiwale)*  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha



## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

Sponsored by  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Submitted to  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 7<sup>th</sup> September 2020 to 23<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjn Roul**  
Assistant Professor  
Department of Pharmacology  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing Capsule identified as **Winostress** (Batch No. 5201030001).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghri), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Winostress** (Batch No. 5201030001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Winostress** (Batch No. 5201030001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Winostress** (Batch No. 5201030001) was more than 2000 mg/kg.


**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Mehga), Wardha.

**Principal investigator**


: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**

: Mr  
Asst  
I.P.E.R. Wardha



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Mehga), Wardha

)/

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

**REPORT**  
**STUDY TITLE**  
**ACUTE ORAL TOXICITY TEST IN THE RATS**  
**-Fixed Dose Procedure-**

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024


Date of commencement: 7<sup>th</sup> September 2020 to 23<sup>rd</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjjan Roul**  
Assistant Professor  
Department  
Institute of Pharmace  
Borgaon



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	





## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing Tablets identified as **Painquit** (Batch No. 5202420001).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was dissolved in water.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2000 mg/kg.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix IV of the present report) the test was performed with 5 animals receiving the test sub  
weight.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Painquit** (Batch No. 5202420001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Painquit** (Batch No. 5202420001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Painquit** (Batch No. 5202420001) was more than 2000 mg/kg.


**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.

**Principal investigator**


: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**

:



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



**Performing Department**

Department of Pharmacology,

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 4<sup>th</sup> September 2020 to 20<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjana Roul**  
Assistant Professor  
Department of Pharmacology  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha




*(Signature)*  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7

APPENDICES



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing semi-solid viscous material identified as: **Chyawan Yogue** (Batch No. 520246001).

The test substance was stored at amb



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha





## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Chyawan Yogue** (Batch No. 5202460001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Chyawan Yogue** (Batch No. 5202460001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Chyawan Yogue** (Batch No. 5202460001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjivale  
I/c Principal  
I.P.E.R. Wardha




**PRINCIPAL**

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**

:  
I.P.E.R. Wardha



(Dr. R. O. Ganjivale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha



# PROJECT REPORT

## ACUTE DERMAL TOXICITY STUDY OF DIABO YOGUE

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



*(Dr. R. O. Ganjwale)*

**Principal**

**PRINCIPAL**

**Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha**

# REPORT

## STUDY TITLE

# ACUTE DERMAL TOXICITY STUDY OF DIABO YOGUE

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024



**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 8<sup>th</sup> September 2020 to 24<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. J.**  
Assi  
Departme  
Institute of Pharmaceuucal Education and Research,  
Borgaon (Meghe), Wardha



(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## TABLE OF CONTENT

<b>SR. NO.</b>	<b>TITLE</b>	<b>PAGE NO.</b>
1.	INTRODUCTION	4
2.	MATERIALS AND METHODS	4
3.	RESULTS	8
4.	DISCUSSION	12
5.	CONCLUSION	12
6.	REFERENCE	13

### LIST OF TABLES

TABLE NO.	TITLE	PAGE NO.
1.	GROUPS OF ANIMALS	5
2.	MEAN BODY WEIGHT	8
3.	MORTALITY	8
4.	FOOD CONSUMPTION (g / animal)	9
5.	BIOCHEMICAL FINDING	9
6.	PATHOLOGY FINDINGS	9

### LIST OF PLATES

PLATE NO.	TITLE	PAGE NO.
1.	Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100	10
2.	Histopathological Studies of Kidney (Group II (2000 mg/kg) (H&E) X100	10
3.	Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400	11
4.	Histopathological Studies of Heart (Group II 2000 mg/kg) X400	11



## 1. INTRODUCTION

Acute dermal toxicity is the adverse effects occurring within a short time of dermal application of a single dose of a test substance. In the assessment and evaluation of the toxic characteristics of a substance, determination of acute dermal toxicity is useful where exposure by the dermal route is likely. It provides information on health hazards likely to arise from a short-term exposure by the dermal route. Data from an acute dermal toxicity study may serve as a basis for classification and labelling. It is an initial step in establishing a dosage regimen in subchronic and other studies and may provide information on dermal absorption and the mode of toxic action of a substance by this route. (OECD Guideline 402)

### OBJECTIVE:

To determine the acute dermal toxicity (if any) of the test sample **Diabo Yogue** (Batch No. 1301) supplied by Siddhayu Healthcare Private Limited Nagpur.

### PRINCIPLE:

The test substance is applied to the skin in graduated doses to several groups of experimental animals, one dose being used per group. Subsequently, observations of effects and deaths are made. Animals which die during the test are necropsied. The surviving animals are sacrificed and necropsied. Animals showing severe and enduring signs of distress and pain may need to be humanely killed. Dosing test substances in a way known to cause marked pain and distress due to corrosive or irritating properties need not be carried out. (OECD Guideline 402)

## 2. MATERIALS AND METHODS

**Test Substance:** The supplier provided for the test container containing cream identified as **Diabo Yogue** (Batch No. 1301)

The test substance was stored at ambient temperature and out of the light

### Details of test animals

**Species:** Albino rats weighing in range


**Strain:** Wistar

**Sex:** Female

**Number of animals per dose level:** 3

**Number of groups:** 2



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha



**Selected doses:** 200 and 2000 mg/kg

**Rationale of selection:** As per OECD 402 guidelines

**Housing and feeding conditions**

Animals were caged individually. The temperature of the experimental animal room was 22°C ( $\pm 3^\circ$ ) and the relative humidity 30-70 per cent. Cages maintained at 12 hr of light and dark cycle in the animal house of the Institute.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Allocation of animals to various groups:**

**Table No. 1. GROUPS OF ANIMALS**

Group No.	Dose (mg/kg b. Wt) Topically	Animal Numbers
I	200	1 – 3
II	2000	4 – 6

### Preparations

Healthy young adult rats were acclimatized to the laboratory conditions for 5 days prior to the test. Before the test, animals were randomized and assigned to the treatment groups. Approximately 24 hours before the test, fur was removed from the dorsal area of the trunk of the test animals by shaving. Care was taken to avoid abrading the skin, which could alter its permeability.

About 10 per cent of the body surface area was clear for the application of the test substance.

### EXPERIMENTAL:

The animals were fasted overnight. Following the period of fasting, the compound was applied on the fur-removed skin. A control group was withheld for 1-2 hours. If the compound are likely to be non-toxic i.e. having toxicity only above regulatory limit dose then, the dose level to be used as the starting dose is



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Meghe), Wardha

selected as 200 mg/kg b. wt. Accordingly, the first dose in this study was 200 mg/kg (topically) and after that as no toxicity occurred; a limit test dose of 2000 mg/kg b. wt. (topically) was taken. Body weight of the entire test animal was recorded before and periodically (weekly) after administration of the test sample. The animal were observed for 24 hours, then for further 1 days for death and manifestation of toxic effects like changes in skin and fur, eyes and mucous membranes and also any changes in respiratory, circulatory, CNS, autonomic, somatic activity and behaviour pattern if any was recorded. The important clinical sign like muscular tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma if any observed during study period were recorded.

#### **Acute Dermal Toxicity (OECD-402)**

For the product of topical application, the testing was undertaken as per OECD-402 guidelines to conduct acute dermal toxicity study test. The Original acute dermal toxicity guideline 402 was adopted in 1987. In this study, both local and systemic effects were investigated. For acute dermal toxicity test 06 Wister rats were procured from CPCSEA registered breeding source i.e. Small Animal Facility, of IPER, Wardha and the test was conducted as per OECD-402 guidelines.

#### **OBSERVATIONS:**

The animals were clinically observed twice on the day of the dosing and once daily thereafter for 14 days.

##### **1. Clinical signs:**

All animals were observed daily for clinical signs such as gross changes in the activity and the behavioral pattern. They were also observed for the presence of tremors, convulsions, salivation, diarrhea and lethargy.

##### **2. Body weight:**

The mean group body weight of the control and test group animals was recorded on 0<sup>th</sup> day, 7<sup>th</sup> day and 14<sup>th</sup> day.

##### **3. Mortality:**

All animals were observed twice daily for mortality during the period of the study.

##### **4. Food consumption:**

The quantities of food consumed by control and test groups were recorded on 0<sup>th</sup> day, 7<sup>th</sup> day and on 14<sup>th</sup> day.



## 5. Biochemical Parameters:

- Aspartate aminotransferase (AST),
- Alanine transaminase (ALT),
- Alkaline phosphatase (ALP)
- Creatinine

## 6. Gross pathology and Histopathology:

All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically. Gross pathology and histopathological examination of lung, Liver, Kidney, and heart were conducted.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings histopathological examination
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

### 3. RESULTS

#### Clinical signs:

All the groups were free of intoxication signs throughout the period of study.

#### Body weight:

Animals from control and test groups exhibited normal and comparable body weight gain throughout the period of study. (Table No. 2)

**Table No. 2 INDIVIDUAL BODY WEIGHT**

Group No.	Dose (mg/kg) Topically	Rats No.	Body weight (g)		
			0 <sup>th</sup> day	7 <sup>th</sup> day	14 <sup>th</sup> day
I	200	1	208	210	221
		2	212	215	225
		3	202	202	206
		Mean±SD	207.33±5.03	209±6.56	217.33±10.02
II	2000	4	221	222	225
		5	236	236	226
		6	226	230	241
		Mean±SD	227.67±7.64	229.33±7.02	230.67±8.96

Values expressed as mean ± standard deviation

#### Mortality: (Table No. 3)

All animals from control group and test group survived throughout the study for 14 days.

**Table No. 3 MORTALITY**

Under the condition of the present study, the following mortality rates were recorded

Group No.	Dose (mg/kg) Body weight (g) topically	Mortality
I	200	0/3
II		



(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Mogha), Wardha

**Food consumption**

**Table No. 4 GROUP MEAN FOOD CONSUMPTION (g / animal)**

Group No.	Dose (mg/kg)	Day		
		0 <sup>th</sup>	7 <sup>th</sup>	14 <sup>th</sup>
I	200	11	12	13
II	2000	12	13	13

**Biochemical Parameter**

**Table No. 5: BIOCHEMICAL FINDING**

Group No.	Dose	AST (IU/L)	ALT (IU/L)	ALP (IU/L)	Creatinine (mg/dL)
I	200 mg/ kg b. wt topically	50.33±4.16	70.33±5.03	76.33±.51	1.33±0.21
II	2000 mg/ kg b. wt topically	62.33±5.51	81.33±3.79	84.7±4.16	1.57±0.32
<b>Significance /NS</b>		<b>NS</b>	<b>NS</b>	<b>NS</b>	<b>NS</b>

Values are expressed as mean ± SD, NS=Non significant

**Gross pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table 5.

**Table No. 6 PATHOLOGY FINDINGS**

Group No.	Death		Comments
	Day	Reason	
I	Day 15	Sacrifice	NTR
II	Day 15	Sacrifice	NTR

NTR = nothing to report

**Histopathology:** Section from liver shows perivascular lymphoid aggregation.

Section from Lung shows mild pneumonitis.



(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAS  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

th mild  
irkable.

PLATES



Plate 1: Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100




Plate 2: Histopathological Studies of Liver (Group II (2000 mg/kg) (H&E) X100



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha





Plate 3: Histopathological Studies of Lung (Group II (2000 mg/kg) (H&E) X400



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Atgahe), Wardha

Plate 4: Histopathological Studies

#### 4. DISCUSSION:

1. The animals treated at different dose levels with the above test compound Diabo Yogue (Batch No. 1301) in all the groups exhibited normal activity and behavioral pattern.
2. There were no clinical signs of tremors, convulsions, exophthalmia, salivation, diarrhea and lethargy.
3. Animals exhibited normal and comparable body weight gain throughout the period of study.
4. Food intake of normal and animals treated at different dose levels was found to be comparable throughout the tenure of the study.
5. The pathology finding shows no abnormality in any group of animals.

#### 5. CONCLUSION:

The above findings revealed that the Diabo Yogue (Batch No. 1301) supplied by Siddhayu Healthcare Private Limited, Nagpur was found to be safe at doses 200 and 2000 mg/kg when applied locally. None of the animals were found to be moribund condition in all the groups until the 14 days of the study.

The Study has indicated that Diabo Yogue (Batch No. 1301) at dose of 2000 mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of Diabo Yogue (Batch No. 1301) was more than 2000 mg/kg.



## REFERENCES

1. OECD Guideline for Testing of Chemicals, Acute oral Toxicity – Fixed Dose Procedure, 402. Organization for Economic Co-operation and Development, Paris, 9<sup>th</sup> October 2017.
2. OECD – Harmonized Integrated Hazard Classification System for Human Health and Environmental Effects of Chemical Substances – as endorsed by the 28<sup>th</sup> Joint Meeting of the Chemicals Committee and the Working Party on Chemicals, November 1998.
3. OECD (2000) – Guidance Document on the Recognition Assessment and Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety Evaluation. Environmental Health and Safety Monograph Series on Testing and Assessment No. 19.

**Project coordinator**

: Dr. R. O. Ganjiwale

  
PRINCIPAL

I/c Principal, Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.  
I.P.E.R. Wardha

**Principal investigator**

: Dr. B. R. Gandhare

Associate Professor

I.P.E.R. Wardha




**Co-Principal Investigator**

: Mr. Jyotiranjun Roul

Assistant Professor





  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

Date of commencement: 5<sup>th</sup> September 2020 to 21<sup>st</sup> September 2020


**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjnan Roul**  
Assistant Professor

Depa  
Institute of Phar  
Bo



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7
APPENDICES	



*(Signature)*  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

## *ACUTE ORAL TOXICITY TEST IN THE RATS - FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>*

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as: **Heart Yogues** (Batch No. 520233001).

The test substance was stored at ambient temperature and out of the light.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Moghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix with 5 animals receiving the test s weight.



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgun (Moghe), Wardha

ormed  
f body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg


- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg < LD<sub>50</sub> < 2000 mg/kg

- Category 5 = LD<sub>50</sub> >

- Category 5 or non class



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance Heart Yogue (Batch No. 520233001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the hazard category 5 or unclassified with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that Heart Yogue (Batch No. 520233001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of Heart Yogue (Batch No. 520233001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha



**PRINCIPAL**

Institute of Pharmaceutical Education & Research  
Borgaon (Meyhe), Wardha.


**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meyhe), Wardha

I.P.E.R. Wardha





# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

I/c Principal

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**

**Dr. B. R. Gandhare**

Associate Professor

Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha



**Performing Department**

Department of Pharmacology,

Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe) Wardha

SEP



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024


Date of commencement: 4<sup>th</sup> September 2020 to 20<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. J. J. Jadhav**  
Ass  
Department  
Institute of Pharmac  
Borgaon (Meghe), Wardha



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

<b>I. AIM AND OBJECTIVES</b>	<b>3</b>
<b>II. TEST SUBSTANCE</b>	<b>3</b>
<b>III. TEST ANIMALS</b>	<b>4</b>
<b>IV. TEST PROCEDURE</b>	<b>4</b>
<b>V. OBSERVATIONS</b>	<b>5</b>
<b>VI. RESULTS</b>	<b>6</b>
<b>VII. CONCLUSION</b>	<b>6</b>
<b>VIII. REFERENCES</b>	<b>7</b>
<b>APPENDICES</b>	



## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.

This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as: **Immune Yogurt** (Batch No. 5202470001).

The test substance was stored at ambient temperature and out of the light.



### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 160-180 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.

The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix with 5 animals receiving the test weight.



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnour (Moghe), Wardha

formed  
f body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg

- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg

- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg

- Category 4 = 300 mg/kg < LD<sub>50</sub> < 2000 mg/kg

- Category 5 = LD<sub>50</sub> >

- Category 5 or non classified



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Immune Yogue** (Batch No. 5202470001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Immune Yogue** (Batch No. 5202470001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Immune Yogue** (Batch No. 5202470001) was more than 2000 mg/kg.


**Project coordinator**

: Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.


**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator**



  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhaya Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjwale**

**W/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,**

**Boi**



**(Dr. R. O. Ganjwale)**

**Principal**

**PRINCIPAL**

**Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha**



# REPORT

## STUDY TITLE

### ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024


Date of commencement: 5<sup>th</sup> September 2020 to 21<sup>st</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal Investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjana Roul**  
As  
Department  
Institute of Pharmaceutical  
Borgaon




  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## CONTENTS

<b>I. AIM AND OBJECTIVES</b>	<b>3</b>
<b>II. TEST SUBSTANCE</b>	<b>3</b>
<b>III. TEST ANIMALS</b>	<b>4</b>
<b>IV. TEST PROCEDURE</b>	<b>4</b>
<b>V. OBSERVATIONS</b>	<b>5</b>
<b>VI. RESULTS</b>	<b>6</b>
<b>VII. CONCLUSION</b>	<b>6</b>
<b>VIII. REFERENCES</b>	<b>7</b>

### APPENDICES



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

## **ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>**

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing liquid preparation identified as: **Digeer Yogee** (Batch No. 5202350001).

The test substance was stored at am



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgnon (Meghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was administered without dilution.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2ml/100g rat.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix 1) with 5 animals receiving the test substance. The study was performed of body weight.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Moghe), Wardha

performed  
of body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were scarified by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.


**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> < 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Mighe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.

**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.


## VII. CONCLUSION

According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Digeer Yogee** (Batch No. 5202350001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Digeer Yogee** (Batch No. 5202350001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Digeer Yogee** (Batch No. 5202350001) was more than 2000 mg/kg.

**Project coordinator**

: Dr. R. O. Ganjivale  
I/c Principal  
I.P.E.R, Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.

**Principal investigator**

: Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R, Wardha



**Co-Principal Investigator**

: Mr. Jyotiranjana Roul  
Assistant Professor  
I.P.E.R, Wardha



# PROJECT REPORT

## ACUTE ORAL TOXICITY TEST IN THE RATS

*Submitted to*

*Siddhayu Healthcare Pvt. Ltd,  
Nagpur 440024*

**Submitted By**

**Project coordinator**

**Dr. R. O. Ganjiwale**

**I/c Principal**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

**Principal investigator**

**Dr. B. R. Gandhare**

**Associate Professor**

**Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**



**Performing Department**

**Department of Pharmacology,**

**Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha**

SEPI



(Dr. R. O. Ganjiwale)

Principal

PRINCIPAL

Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha

## REPORT

### STUDY TITLE

# ACUTE ORAL TOXICITY TEST IN THE RATS -Fixed Dose Procedure-

**Sponsored by**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024

**Submitted to**  
Siddhayu Healthcare Pvt. Ltd.  
Nagpur, 440024


Date of commencement: 8<sup>th</sup> September 2020 to 24<sup>th</sup> September 2020

**Project coordinator**  
**Dr. R. O. Ganjiwale**  
I/c Principal  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Principal investigator**  
**Dr. B. R. Gandhare**  
Associate Professor  
Department of Pharmacology,  
Institute of Pharmaceutical Education and Research,  
Borgaon (Meghe), Wardha

**Co-Principal Investigator**  
**Mr. Jyotiranjana Roul**  
Assis  
Department  
Institute of Pharmace  
Borgaon



  
(Dr. R. O. Ganjiwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha




## CONTENTS

I. AIM AND OBJECTIVES	3
II. TEST SUBSTANCE	3
III. TEST ANIMALS	4
IV. TEST PROCEDURE	4
V. OBSERVATIONS	5
VI. RESULTS	6
VII. CONCLUSION	6
VIII. REFERENCES	7

### APPENDICES



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Dorgaon (Moghe), Wardha

## ***ACUTE ORAL TOXICITY TEST IN THE RATS – FIXED DOSE PROCEDURE METHOD- OECD GUIDELINE 420<sup>1</sup>***

### **I. AIM & OBJECTIVE OF THE TEST**

The aim of the test is to obtain, using a minimum number of animals, sufficient information on the acute toxicity after single administration, by oral route in the rat, of a test substance, for its classification.

The test substance is administered to a group of experimental animals, by oral route at one defined dose (5 mg/kg, 50 mg/kg, 300 mg/kg or 2000 mg/kg) according to the available information on the test substance.

The animals are observed each day for 14 days at least, after administration, to detect the signs of toxicity. Animals which die are necropsied; the animals which are intercurrently sacrificed as well as the ones which survive until the end of the test are necropsied.


This test using pre-defined doses provides results allowing the test substance to be ranked according to the Globally Harmonised System (GHS) for classification of chemicals which cause acute toxicity (OECD 1998).<sup>2</sup>

### **II. TEST SUBSTANCE**

The supplier provided for the test container containing powder identified as **Turmeric Yogue** (Batch No. 5202400001).

The test substance was stored at ambie



  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borguon (Meghe), Wardha

### III. TEST ANIMALS

**Species:** Albino rats weighing in range of 180-200 g

**Strain:** Wister

**Age:** 8-12 weeks

**Number & Sex:** 5 nulliparous and non-pregnant females.

**Diet:** Standard feed prepared in-house.

**Water:** Plain tap water *ad libitum*.

**Housing:** The animals were housed in 37cm x 23cm x 16cm polypropylene cages with maximum 3 animals per cage. The cages were placed in limited-access premises of animal house with controlled temperature and humidity. The artificial lighting ensured a sequence of 12 hours light and 12 hours dark.

### IV. TEST PROCEDURE

**Preparation of the test substance:** The test substance was dissolved in water.

**Administration of the test substance:** The animals fasted overnight prior to the test substance administration. All animals were weighed again on day 1 before administration.


The volume per 100 g of body weight, defined to 2 ml/100g, the volume to administer was calculated for each rat.

The test substance was administered in a single dose, orally by gavage using a syringe fitted with suitable sized canula. After administration, animals were fasted for 3-4 hours.

**Selection of starting dose:** As the test substance was an Ayurvedic formulation the starting dose was selected as 2000 mg/kg.

**Main study:** According to the methodology describe in the Annex 3 of the OECD guideline 420 (joined in Appendix 1) with 5 animals receiving the test substance of body weight.



  
(Dr. R. O. Ganjwale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoun (Meghe), Wardha

formed  
f body

## V. OBSERVATIONS

Animals were observed individually after dosing during the first 30 minutes, periodically during the first 24 hours and daily thereafter for a total of 14 days.

The clinical observations were made individually, each animal being examined outside the home cage.

The different parameters observed were – changes in skin & fur, eyes & mucous membranes, respiratory function, tremors, convulsions, salivation, diarrhea, lethargy, sleep & coma.<sup>3</sup>

**Body weight:** The animals were regularly weighed on day 1 before administration, then on day 8 and day 15 i.e. 7 and 14 days after administration of the test substance.

**Pathology:** All the animals surviving at the end of the 14 days of observation were sacrificed by intraperitoneal injection of 6% sodium pentobarbital solution at the rate of 0.12 ml/100g and bled at the femoral artery. They were necropsied and the main organs were examined macroscopically.

**Interpretation of the results:** The assessment criteria of the toxicity of the test substance taken into account were:

- Body weight change
- Clinical and behavioral signs
- Necropsy findings
- The mortality expressed in % of compound related deaths.

These results enabled to classify the test substance to one of a series of toxicity classes defined by fixed oral LD<sub>50</sub> cut-off values, in compliance with Globally Harmonized System (GHS).<sup>2</sup>

- Category 1 = 0 < LD<sub>50</sub> < 5 mg/kg
- Category 2 = 5 mg/kg < LD<sub>50</sub> < 50 mg/kg
- Category 3 = 50 mg/kg < LD<sub>50</sub> < 300 mg/kg
- Category 4 = 300 mg/kg < LD<sub>50</sub> ≤ 2000 mg/kg
- Category 5 = LD<sub>50</sub> >
- Category 5 or non classified



*(Signature)*  
(Dr. R. O. Ganjivale)  
Principal  
PRINCIPAL  
Institute of Pharmaceutical Education & Research  
Borgoa (Moghe), Wardha

## VI. RESULTS

**Body weight:** All animals exhibited normal and comparable body weight gain throughout the period of study. The individual weights of the animals assessed during the test are supplied in Appendix I.

**Clinical Observations:** All animals were free of intoxication signs throughout the period of study. The results of the clinical observations are summarized in the table enclosed in Appendix II.


**Pathology:** All main organs subjected to necropsy were found normal in all animals. The result of the necropsy findings are summarized in the table enclosed in Appendix III.

## VII. CONCLUSION


According to the Globally Harmonized System (GHS) for the classification of substances which cause acute toxicity, the substance **Turmeric Yogue** (Batch No. 5202400001), supplied by Siddhayu Ayurvedic Research Foundation Pvt. Ltd., Nagpur was classified in the **hazard category 5 or unclassified** with a LD<sub>50</sub> higher than 2000 mg/kg in the Rat.

The Study has indicated that **Turmeric Yogue** (Batch No. 5202400001) at dose of 2000mg/kg did not affect general health of Wistar rats. There were no gross abnormalities observed in necropsied rats. Based on this, minimal lethal dose of **Turmeric Yogue** (Batch No. 5202400001) was more than 2000 mg/kg.


**Project coordinator** : Dr. R. O. Ganjiwale  
I/c Principal  
I.P.E.R. Wardha

  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha.

**Principal investigator** : Dr. B. R. Gandhare  
Associate Professor  
I.P.E.R. Wardha



**Co-Principal Investigator** :   
I.P.E.R. Wardha

  
(Dr. R. O. Ganjiwale)  
Principal  
**PRINCIPAL**  
Institute of Pharmaceutical Education & Research  
Borgaon (Meghe), Wardha